Acalabrutinib-D4
| Product Name | Acalabrutinib-D4 |
|---|---|
| Alternate Names | Acalabrutinib Stable Isotopes, Stable Isotopes of Acalabrutinib |
| CAT No. | CS-CX-00575 |
| CAS No. | 1420477-60-6 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | Not Available |
| Mol. For. | Not Available |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Acalabrutinib |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | O=C(N(CCC1)[C@@H]1C2=NC(C3=CC=C(C(NC4=C([2H])C([2H])=C([2H])C([2H])=N4)=O)C=C3)=C5N2C=CN=C5N)C#CC |
| Canonical Smiles | CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5 |
| InchIKey | WDENQIQQYWYTPO-IBGZPJMESA-N |
| Inchl | InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1 |
| IUPAC | 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Acalabrutinib-D4 is a deuterated derivative of Acalabrutinib, a potent and selective inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a key component of the B-cell receptor (BCR) signaling pathway, which is essential for the survival and proliferation of B-cells. Acalabrutinib-D4 is used in biological research and clinical trials to study the pharmacokinetics and pharmacodynamics of Acalabrutinib.
Chemically, Acalabrutinib-D4 is a deuterated analog of Acalabrutinib, with four deuterium atoms incorporated into the molecule. Deuteration is a common technique in drug development, as it can improve the pharmacokinetic properties of a molecule by increasing its stability and reducing its metabolism and clearance. The deuterium atoms in Acalabrutinib-D4 are located on the phenyl ring of the molecule, which is involved in the binding of the inhibitor to BTK.
Acalabrutinib-D4 is typically administered orally, and its pharmacokinetic properties have been characterized in preclinical studies. It has been shown to have similar potency and selectivity for BTK as Acalabrutinib, and to exhibit a longer half-life and reduced clearance in vivo. Acalabrutinib-D4 is also used as a reference standard in analytical chemistry, to aid in the identification and quantification of Acalabrutinib in biological samples.
Get an Instant Quote
Related Compounds
Acalabrutinib Metabolite (M27) ACP-5862 D4 | Acalabrutinib intermediate D4 | Acalabrutinib-d3 |